Clinical Trials · NCT00887354

A Study That Will Compare the Effect of Two Drugs on Participants With Low Bone Mass and a Recent Hip Fracture

CompletedPhase 4Teriparatide (Approved)
Phase
Phase 4
Recruitment status
Completed
Sponsor
Eli Lilly and Company
Enrollment
224
Start date
Apr 2009
Locations
28 sites, 12 countries
Primary endpoint
Change in Lumbar Spine Areal Bone Mineral Density (BMD)
View Teriparatide compound reference